Stockreport

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases [Yahoo! Finance]

Cue Biopharma, Inc.  (CUE) 
US:NASDAQ Investor Relations: cuebiopharma.gcs-web.com/news-releases
PDF The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to a [Read more]